The iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma
Background: Reliable biomarkers are rare for renal cell carcinoma (RCC) treatment selection. We aimed to discover novel biomarkers for precision medicine. The iron-regulating hormone hepcidin (HAMP) was reportedly increased in RCC patient sera and tissues. However, its potential implication as a pro...
Saved in:
Main Authors: | Jian Huang (Author), Wang Liu (Author), Shiqi Song (Author), Jean C. Li (Author), Kaimei Gan (Author), Chunxiao Shen (Author), Jeffrey Holzbeierlein (Author), Benyi Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High Hepcidin expression predicts poor prognosis in patients with clear cell renal cell carcinoma
by: Yuting Tang, et al.
Published: (2022) -
Iron, hepcidin and the metal connection.
by: Olivier eLoréal, et al.
Published: (2014) -
Iron, anemia and hepcidin in malaria
by: Natasha eSpottiswoode, et al.
Published: (2014) -
Iron deficiency in the elderly population, revisited in the hepcidin era
by: Fabiana eBusti, et al.
Published: (2014) -
Erythroferrone and hepcidin levels in children with iron deficiency anemia
by: Ramazan Dulkadir, et al.
Published: (2024)